Pathway to Cures
Pathway to Cures is a nonprofit venture philanthropy fund that invests in early-stage biotech companies developing therapies for inheritable blood and bleeding disorders. Established in 2022 by the National Bleeding Disorders Foundation, the fund operates from New York with a $3.5M initial commitment.
- Company typePrivate
- Founded2022
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Pathway to Cures does
Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund launched in September 2022 by the National Bleeding Disorders Foundation (NBDF, formerly National Hemophilia Foundation). The fund addresses an early-stage funding gap for biotech companies developing therapies for inheritable blood and bleeding disorders — a disease area affecting more than 20 million people globally — with particular focus on underserved conditions beyond hemophilia A and B, including von Willebrand disease, sickle cell disease, thalassemia, and rare factor deficiencies. P2C operates as an evergreen investment vehicle with an initial $3.5 million commitment from NBDF and a stated fundraising target of $20 million; minimum donor commitments are $500,000.
P2C's core activity is direct equity and partnership investment in early-stage biotech companies, with all realized investment returns reinvested back into the fund to compound mission impact. Its portfolio spans six companies and six therapeutic modalities: Anvesana (antisense oligonucleotides for hemophilia and Factor XI deficiency), Afimmune (Epeleuton small molecule for sickle cell disease and thalassemia), Be Biopharma (engineered B-cell medicines for hemophilia B, in Phase 1/2), Spark Biomedical / Five Liters (non-invasive vagus nerve stimulation for von Willebrand disease and heavy menstrual bleeding, with the OhmBody wellness brand), Seawolf Therapeutics (non-viral DNA delivery for hemophilia A and B), and SeraGene Therapeutics (RNA-based lipid nanoparticle therapies for coagulation disorders, headquartered in Vancouver). Investments are evaluated by an Investment Committee and a Scientific Advisory Group comprising world-renowned hematology and gene therapy experts.
P2C's go-to-market model leverages NBDF's 75-year legacy in bleeding disorders, including access to the Community Voices in Research patient registry, 50 U.S. chapters, and deep relationships with clinical experts at leading treatment centers (Yale, OHSU, University of Michigan, Nationwide Children's). The fund reaches donors, biotech partners, and the patient community through its website, LinkedIn, The Pathway Pulse newsletter, press releases, webinars, and industry conferences. P2C is headquartered at 1230 Avenue of the Americas, New York, NY, and operates with a lean team of 1–10 employees.
Pathway to Cures firmographics
Firmographics- Name
- Pathway to Cures
- Legal name
- Pathway to Cures
- Website
- https://pathwaytocures.org
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Pathway to Cures is a nonprofit venture philanthropy fund that invests in early-stage biotech companies developing therapies for inheritable blood and bleeding disorders. Established in 2022 by the National Bleeding Disorders Foundation, the fund operates from New York with a $3.5M initial commitment.
- Ownership category
- akta.pro rank
Pathway to Cures industry classification
Industry- Product category
- Venture Philanthropy Fund
- NAICS
- Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
- SIC
- Services-Misc Health & Allied Services, Nec (8090), Services-Social Services (8300)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Research & Science Grantmaking Foundations (BPAGAKAI), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
Keywords
Where Pathway to Cures is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pathway to Cures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Distribution channels1 record
Marketing channels7 records
Pathway to Cures product offering
Product offeringCore offering
Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund that invests philanthropic and investment capital in early-stage biotechnology companies developing transformational therapies and technologies for inheritable blood and bleeding disorders. The fund combines charitable donations (minimum $500,000) with venture-style equity investments in portfolio companies, reinvesting all returns back into the fund to amplify mission impact. It does not sell products or services directly; instead, it deploys capital, scientific advisory support, and access to NBDF's patient registry and clinical networks to portfolio companies.
Product overview
Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation, not a product company. It does not sell products or services directly. Instead, it operates as an investment vehicle that funds biotech companies developing therapies for inheritable blood and bleeding disorders. The fund's portfolio includes investments in six biotech companies: Anvesana (ASO therapeutics for bleeding disorders), Afimmune (Epeleuton for sickle cell disease and thalassemia), Be Biopharma (engineered B-cell medicine for hemophilia B), Spark Biomedical/OhmBody (non-invasive wearable neurostimulation device for von Willebrand disease and heavy menstrual bleeding), Seawolf Therapeutics (non-viral DNA delivery platform for hemophilia A and B), and SeraGene Therapeutics (RNA-based therapies using lipid nanoparticles for von Willebrand disease with focus on women's health). The fund's role is investment and strategic guidance, not direct product provision.
Differentiator
Problem solved
Functional benefit
Products and services
- Pathway to Cures Venture Philanthropy Fund An evergreen nonprofit venture philanthropy fund that provides early-stage equity investment, strategic guidance, and access to the National Bleeding Disorders Foundation's patient registry and scientific advisory network to biotech companies developing therapies for inheritable blood and bleeding disorders.
- Venture Philanthropy Donor Program A donation program accepting transformational contributions (minimum $500,000) from individuals, groups, and institutions. Donations are deployed as mission-aligned investments in portfolio biotechs, with returns reinvested into the fund.
Companies that use Pathway to Cures
Customer profileSegments3 records
Ideal customer profiles2 records
Pathway to Cures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Pathway to Cures partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- National Bleeding Disorders Foundation (NBDF)coreNBDF is the parent organization of Pathway to Cures. P2C is NBDF's venture philanthropy fund created to accelerate the development of cures across all inheritable blood and bleeding disorders. NBDF provides funding, patient registry access (Community Voices in Research), scientific community relationships, and advisory panel programs.
- Feinstein Institutes for Medical ResearchcoreThe Feinstein Institutes at Northwell Health conducted over 20 years of research on vagus nerve stimulation and hemostasis that underlies Spark Biomedical's technology. Dr. Kevin Tracey is a co-author on key Nature Communications research demonstrating the mechanism of action.
- Oregon Health & Science University (OHSU)minorOHSU is a collaborating institution for the LUNA Trial evaluating transcutaneous auricular neurostimulation for heavy menstrual bleeding. Dr. Michael Recht previously served as Director of the Hemophilia Center at OHSU from 2007 until 2020.
- University of MichiganminorUniversity of Michigan is a collaborating institution for the LUNA Trial. Dr. Steven Pipe, a member of P2C's Scientific Advisory Group, is a Professor at the University of Michigan and Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program.
- Yale UniversityminorYale University is a collaborating institution for the LUNA Trial. Dr. Michael Recht serves as Professor of Clinical Pediatrics at Yale University School of Medicine and is P2C's Chief Medical and Scientific Advisor.
- Portal InnovationsminorPortal Innovations is a laboratory incubator facility in Chicago's Fulton Market district (and Atlanta's Science Square) where P2C holds its fund update meetings and portfolio companies can access laboratory space.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Pathway to Cures competitors and assessment
Company assessmentDirect peers
- Friedreich's Ataxia Research Alliance (FARA): FARA funds biotech development for Friedreich's ataxia, a rare inherited disease, using venture philanthropy tactics including direct biotech investments. Comparable to P2C as a small rare-disease venture philanthropy organization.
- Alzheimer's Drug Discovery Foundation: ADDF is a venture philanthropy foundation funding early-stage Alzheimer's drug development with biotech-focused investments and scientific advisory networks. Comparable to P2C in structure (nonprofit biotech investor) and patient-mission orientation.
- JDRF T1D Fund: Venture philanthropy fund of JDRF (Juvenile Diabetes Research Foundation) investing in Type 1 diabetes therapeutics. Directly comparable to P2C as a disease-focused philanthropic venture fund leveraging a parent patient-advocacy organization and reinvesting returns.
- Cystic Fibrosis Foundation: The pioneering rare-disease venture philanthropy organization that funded development of Kalydeco, Trikafta, and other CFTR modulators. Directly comparable to P2C as a patient-founded venture philanthropy vehicle funding early-stage biotech for a single rare disease, with returns reinvested into mission.
- Multiple Myeloma Research Foundation (Myeloma Investment Fund): MMRF's Myeloma Investment Fund is a venture philanthropy vehicle that has funded numerous myeloma therapies to approval. Directly comparable as a disease-specific venture philanthropy arm using donor capital to underwrite early-stage biotech.
- Leukemia & Lymphoma Society Therapy Acceleration Program: LLS's Therapy Acceleration Program invests philanthropic capital directly into biotech developing blood cancer therapies. Comparable to P2C as a venture philanthropy arm of a major blood-disease patient organization funding clinical-stage assets.
Broad incumbents
- BioMarin Pharmaceutical: Commercial rare-disease biopharmaceutical company that developed and commercialized Roctavian, the first approved AAV gene therapy for hemophilia A. Comparable to P2C as the strategic acquirer/integrator that venture philanthropy-backed hemophilia assets eventually flow toward.
Emerging players
- Charcot-Marie-Tooth Association (CMTA): CMTA funds research and biotech development for Charcot-Marie-Tooth disease, a rare inherited neurological disorder. Comparable to P2C as a smaller rare inherited disease venture philanthropy organization building a portfolio of therapeutic investments.
- Alex's Lemonade Stand Foundation: Childhood cancer research nonprofit that has expanded into biotech venture investments. Comparable to P2C as a smaller-scale philanthropic research investor in a specific disease area.
- Parent Project Muscular Dystrophy: PPMD funds Duchenne muscular dystrophy research and has backed biotech programs. Comparable to P2C as a rare inherited disease venture philanthropy organization leveraging patient community expertise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Pathway to Cures social profiles
Digital presencePathway to Cures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pathway to Cures leadership team
Management profileNumber of profiles
Profiles19 records
Pathway to Cures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pathway to Cures M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pathway to Cures
What does Pathway to Cures do?
Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund that invests philanthropic and investment capital in early-stage biotechnology companies developing transformational therapies and technologies for inheritable blood and bleeding disorders. The fund combines charitable donations (minimum $500,000) with venture-style equity investments in portfolio companies, reinvesting all returns back into the fund to amplify mission impact. It does not sell products or services directly; instead, it deploys capital, scientific advisory support, and access to NBDF's patient registry and clinical networks to portfolio companies.
Is Pathway to Cures a public or private company?
Pathway to Cures is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Pathway to Cures founded?
Pathway to Cures was founded in 2022. It employs 1 to 10 people.
Where is Pathway to Cures based?
Pathway to Cures is headquartered in New York, United States, in the North America region.
Who are Pathway to Cures's main competitors?
Direct peers on record are Friedreich's Ataxia Research Alliance (FARA), Alzheimer's Drug Discovery Foundation, JDRF T1D Fund, Cystic Fibrosis Foundation, Multiple Myeloma Research Foundation (Myeloma Investment Fund) and Leukemia & Lymphoma Society Therapy Acceleration Program. BioMarin Pharmaceutical is listed as a broad incumbent. Emerging players are Charcot-Marie-Tooth Association (CMTA), Alex's Lemonade Stand Foundation and Parent Project Muscular Dystrophy.
Does Pathway to Cures have an API?
No public API is recorded for Pathway to Cures.
What industry is Pathway to Cures in?
Pathway to Cures's product category is Venture Philanthropy Fund. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8090.